CBLIF

Across TCGA pan-cancer cohorts, CBLIF mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of CBLIF’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where CBLIF mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types CBLIF is over-expressed in tumor, although a few such as HNSC and PDAC show the opposite, repressed pattern.

HNSC and PDAC are the cancer types where CBLIF tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CBLIF mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	II,III,IV	−0.390	.019	6	view →
PDAC	All	All	−0.642	<.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

CBLIF–HNSC

Open the HNSC breakdown →